scholarly journals MA 05.01 Integrating INDEL Mutations into Neoantigen Prediction in Lung Cancer: Developing Personalized Cancer Vaccines

2017 ◽  
Vol 12 (11) ◽  
pp. S1814-S1815
Author(s):  
Y. Lou ◽  
Y. Asmann ◽  
M. Thomas ◽  
K. Knutson
Keyword(s):  
Lung Cancer ◽  
Cancer Vaccines ◽  
Personalized Cancer

Promising Immuno-Oncology Options for the Future: Cellular Therapies and Personalized Cancer Vaccines

2020 ◽  
pp. e253-e258
Author(s):  
Benjamin J. Solomon ◽  
Paul A. Beavis ◽  
Philip K. Darcy
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Cell Therapy ◽  
Cancer Cells ◽  
Cancer Vaccines ◽  
Adoptive Cell Therapy ◽  
Current Status ◽  
Common Pathway ◽  
Personalized Cancer ◽  
Anticancer Response

A common pathway for an effective immune anticancer response involves recognition of tumor neoantigens and subsequent targeting of cancer cells by T cells. In this article, we provide an overview of the current status of two approaches to directly enhance this interaction using either adoptive cell therapy or personalized cancer vaccines with focus on recent advances in solid tumors, including lung cancer.

scholarly journals Making the Most of Complexity to Create Opportunities: Comprehensive Genomic Profiling and Molecular Tumor Board for Patients with Non-Small Cell Lung Cancer (NSCLC)

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 609
Author(s):  
Caterina Fumagalli ◽  
Elena Guerini-Rocco ◽  
Massimo Barberis
Keyword(s):  
Lung Cancer ◽  
Small Cell ◽  
Tumor Board ◽  
Genomic Profiling ◽  
Small Cell Lung ◽  
Molecular Alterations ◽  
Comprehensive Genomic Profiling ◽  
Molecular Tumor Board ◽  
Personalized Cancer Therapy ◽  
Personalized Cancer

Personalized cancer therapy matches the plan of treatment with specific molecular alterations [...]

The Potential of Personalized Cancer Vaccines

2017 ◽  
Vol 39 (18) ◽  
pp. 1
Author(s):  
Danielle Bullen Love
Keyword(s):  
Cancer Vaccines ◽  
Personalized Cancer

Lung Cancer Vaccines

2007 ◽  
Vol 7 (6) ◽  
pp. 469-484 ◽  
Author(s):  
Rob Eager ◽  
Lindsey Harle ◽  
John Nemunaitis
Keyword(s):  
Lung Cancer ◽  
Cancer Vaccines

scholarly journals Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition

Cancers ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 204 ◽  
Author(s):  
Elisabeth Smolle ◽  
Martin Pichler
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Tobacco Smoke ◽  
Treatment Options ◽  
Tumor Biology ◽  
Patient Characteristics ◽  
Driver Genes ◽  
Unique Type ◽  
Personalized Cancer Therapy ◽  
Personalized Cancer

Non-small cell lung cancer (NSCLC) in non-, and especially in never-smoking patients is considered a biologically unique type of lung cancer, since risk factors and tumorigenic conditions, other than tobacco smoke, come into play. In this review article, we comprehensively searched and summarized the current literature with the aim to outline what exactly triggers lung cancer in non-smokers. Changes in the tumor microenvironment, distinct driver genes and genetic pathway alterations that are specific for non-smoking patients, as well as lifestyle-related risk factors apart from tobacco smoke are critically discussed. The data we have reviewed highlights once again the importance of personalized cancer therapy, i.e., careful molecular and genetic assessment of the tumor to provide tailored treatment options with optimum chances of good response—especially for the subgroups of never-smokers.

Lung cancer vaccines and gene therapy

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. 103-113 ◽  
Author(s):  
Kristen M. Hege ◽  
David P. Carbone
Keyword(s):  
Lung Cancer ◽  
Gene Therapy ◽  
Cancer Vaccines

scholarly journals Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

2019 ◽  
Vol 69 (1) ◽  
pp. 135-145 ◽  
Author(s):  
Rui Zhang ◽  
Fengjiao Yuan ◽  
Yang Shu ◽  
Yaomei Tian ◽  
Bailing Zhou ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Immune Responses ◽  
Cancer Vaccines ◽  
Therapeutic Effects ◽  
Mouse Tumor ◽  
Pulsed Dc ◽  
Dendritic Cell Vaccines ◽  
Dc Vaccines ◽  
T Cell Immune Responses ◽  
Personalized Cancer

AbstractDevelopment of personalized cancer vaccines based on neoantigens has become a new direction in cancer immunotherapy. Two forms of cancer vaccines have been widely studied: tumor-associated antigen (including proteins, peptides, or tumor lysates)-pulsed dendritic cell (DC) vaccines and protein- or peptide-adjuvant vaccines. However, different immune modalities may produce different therapeutic effects and immune responses when the same antigen is used. Therefore, it is necessary to choose a more effective neoantigen vaccination method. In this study, we compared the differences in immune and anti-tumor effects between neoantigen-pulsed DC vaccines and neoantigen-adjuvant vaccines using murine lung carcinoma (LL2) candidate neoantigens. The enzyme-linked immunospot (ELISPOT) assay showed that 4/6 of the neoantigen-adjuvant vaccines and 6/6 of the neoantigen-pulsed DC vaccines induced strong T-cell immune responses. Also, 2/6 of the neoantigen-adjuvant vaccines and 5/6 of the neoantigen-pulsed DC vaccines exhibited potent anti-tumor effects. The results indicated that the neoantigen-pulsed DC vaccines were superior to the neoantigen-adjuvant vaccines in both activating immune responses and inhibiting tumor growth. Our fundings provide an experimental basis for the selection of immune modalities for the use of neoantigens in individualized tumor immunotherapies.

Sign in / Sign up

Export Citation Format

Share Document